Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Quality Index
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Quality Index of -0.01x as of June 2024. Operating cash flow of NT$-945.00K is below net income of NT$69.80 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Taigen Biopharmaceuticals Holdings Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Quality Index (2011–2023)
Historical Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is Taigen Biopharmaceuticals Holdings Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd (2011–2023)
Year-by-year earnings quality comparison for Taigen Biopharmaceuticals Holdings Ltd. For live market cap and the full company financial profile, see Taigen Biopharmaceuticals Holdings Ltd (4157) market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.15x | NT$20.74 Million | NT$136.73 Million | ▼ -78.9% |
| 2021 | 0.72x | NT$629.07 Million | NT$875.99 Million | ▲ +300.8% |
| 2017 | -0.36x | NT$-266.93 Million | NT$746.38 Million | ▲ +96.0% |
| 2011 | -8.85x | NT$-379.23 Million | NT$42.84 Million | — |